Wasa Medical Holdings v. Sorrento Therapeutics, Inc. et al

  1. November 19, 2021

    Sorrento Escapes COVID-19 Investor Class Action

    A California federal judge has dismissed a proposed class action from investors in Sorrento Therapeutics Inc. who claimed the company misled the public about its COVID-19 treatment, finding the investors didn't adequately show how the company's statements were misleading.

  2. February 16, 2021

    Robbins Geller To Lead Sorrento COVID-19 Class Action

    Robbins Geller Rudman & Dowd LLP will represent a proposed class of investors in Sorrento Therapeutics Inc. in a federal suit in San Diego alleging that the company misled the public after its CEO characterized some of its COVID-19 research as a "cure."

  3. August 13, 2020

    Sorrento Investors Fight To Lead COVID-19 'Cure' Suit

    Sorrento Therapeutics Inc. investors represented by Pomerantz, Kirby McInerney and Robbins Geller continue to fight for appointment as lead plaintiff in a proposed securities class action accusing the company of misleading the public after its CEO characterized some of its COVID-19 research as a "cure."

  4. May 29, 2020

    COVID-19 Securities Catch-Up: The 8 Biggest Investor Actions

    At least 50 federal securities cases with references to COVID-19 have been filed in the past three months, including merger challenges, regulatory enforcement actions and sprawling investor suits, according to a Law360 review of filings. As the pandemic pushes into the summer, Law360 is taking a look at eight major investor actions that were brought in connection with the novel coronavirus since March.

  5. May 27, 2020

    Sorrento Sued Over COVID-19 'Cure' Comment To Fox News

    Sorrento Therapeutics Inc. was hit with a stock-drop suit on Tuesday over statements its CEO made to Fox News in mid-May that allegedly referred to a recent breakthrough in the company's COVID-19 treatment research as a "cure."